Current Report Filing (8-k)
March 19 2019 - 12:17PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
March 18, 2019
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
|
|
001-37769
|
|
N/A
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
|
|
02142
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
8.01 Other Events.
On
March 18, 2019, VBI Vaccines Inc. announced that Nell Beattie, Chief Business Officer, will present at the Oppenheimer 29
th
Annual Healthcare Conference on March 20, 2019 in New York City. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI Vaccines Inc.
|
|
|
|
Date: March 19, 2019
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff Baxter
|
|
|
President and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2024 to May 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to May 2024